The controlling shareholder of Star Lake Bioscience (600866.SH) has completed the increase in holding of the company's 0.68% stake.
Star Lake Technology (600866.SH) has announced that its controlling shareholder, Guangdong Guangxin Holdings Group Co., Ltd. (abbreviated as...)
Star Lake Bioscience (600866.SH) announced that the controlling shareholder Guangdong Guangxin Holding Group Co., Ltd. (referred to as "Guangxin Group") has completed the implementation of its share increase plan. Guangxin Group has acquired a total of 11.3018 million shares of the company through centralized competitive bidding on the Shanghai Stock Exchange, representing 0.68% of the total share capital of the company. The total amount of the share increase is RMB 51.2965 million. This share increase plan has been completed.
Related Articles
SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.
SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.
On July 2, MNSO (09896) spent $231,100 to repurchase 51,200 shares.
SIMCERE PHARMA(02096): Enze Shu has been approved by the National Medical Products Administration to be launched in China.
SIRNAOMICS-B (02257): Ouyang Yunlong appointed as non-executive director.
On July 2, MNSO (09896) spent $231,100 to repurchase 51,200 shares.
RECOMMEND
U.S. Senate Passes “Big and Beautiful” Bill, Triggering Surge in Gold Amid Soaring Deficit Concerns
02/07/2025
Declining Demand Triggers Price Drop; Photovoltaic Glass Industry May Be Preparing for a New Round of Coordinated Production Cuts
02/07/2025
Surge in Prices of Chinese-Made Goods Highlights Tariff Impact on U.S. Consumers
02/07/2025
